The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 21, No. 5, pp. 450-452.
© 1987 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gervais, A
Right arrow Articles by McLean, W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gervais, A
Right arrow Articles by McLean, W

Research Articles

Digoxin-like immunoreactive substance (DLIS) in liver disease: comparison of clinical and laboratory parameters in patients with and without DLIS

A Gervais, AA Nanji, DC Greenway, and W McLean

Falsely elevated serum digoxin values have recently been reported in patients with liver disease. Since not all patients have circulatory digoxin-like immunoreactive substance (DLIS) in their serum, we compared the clinical and laboratory findings in patients with and without DLIS. Thirty-two patients with liver disease were studied. The only parameter that was significantly different in the two groups was serum bilirubin. In the group of patients with DLIS, significant correlations were obtained between DLIS and bilirubin and DLIS and creatinine. We postulate that increased levels of DLIS in serum are due to an abnormality of DLIS excretion.


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
W. Steimer, C. Muller, and B. Eber
Digoxin Assays: Frequent, Substantial, and Potentially Dangerous Interference by Spironolactone, Canrenone, and Other Steroids
Clin. Chem., March 1, 2002; 48(3): 507 - 516.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1987 by Harvey Whitney Books Company.